Bone Morphogenetic Protein 2 Stimulates Osteoclast Differentiation and Survival Supported by Receptor Activator of Nuclear Factor-κB Ligand
Kanami Itoh(SHOWA Medical University), Naoyuki Takahashi(Matsumoto Dental University), Nobuyuki Udagawa(Matsumoto Dental University), Shun‐ichiro Iemura(Fukushima Medical University), Matthew T. Gillespie(Hudson Institute of Medical Research), Naoto Ueno(University of Hawaiʻi at Mānoa), Hisataka Yasuda(SHOWA Medical University), T. John Martin(St Vincent's Hospital Melbourne), Tatsuo Suda(SHOWA Medical University), Takenobu Katagiri(Saitama Medical University), J Quinn(The University of Melbourne), Kanji Higashio(Megmilk Snow Brand (Japan))
Cited by 246
Related Papers
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
|Proceedings of the National Academy of Sciences|1998|4.3k
Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families
|Endocrine Reviews|1999|2.3k
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
|Journal of Clinical Investigation|1999|1.7k
Tumor Necrosis Factor α Stimulates Osteoclast Differentiation by a Mechanism Independent of the Odf/Rankl–Rank Interaction
|The Journal of Experimental Medicine|2000|1.3k